Michael Anderson

Michael Anderson

Auto-generated profile, based on publicly available information

Michael Anderson

Department of Physiology, University of Maryland School of Medicine

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Immunity
Verified
Journal Article
Closed access
JMJames Meixiong
James Meixiong
MAMichael Anderson
Michael Anderson
NLNathachit Limjunyawong
Nathachit Limjunyawong
MSMark F. Sabbagh
Mark F. Sabbagh
EHEric Hu
Eric Hu
XDXinzhong Dong
Xinzhong Dong

1 September 2016 in Neuron
Verified
Journal Article
Closed access
YKYu Shin Kim
Yu Shin Kim
MAMichael Anderson
Michael Anderson
KPKyoungsook Park
Kyoungsook Park
QZQin Zheng
Qin Zheng
AAAmit Agarwal
Amit Agarwal
XDXinzhong Dong
Xinzhong Dong

18 April 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKSubhash Kulkarni
Subhash Kulkarni
MMMaria-Adelaide Micci
Maria-Adelaide Micci
JLJenna Leser
Jenna Leser
CSChangsik Shin
Changsik Shin
STShiue-Cheng Tang
Shiue-Cheng Tang
PPPankaj J. Pasricha
Pankaj J. Pasricha
Significance: The demonstration of a robust neurogenesis program in the adult gut and the existence of an enteric neural precursor cell (ENPC) responsible for the same has profound biological and clinical implications. This demonstrates the presence of robust adult neurogenesis outside of the CNS, and indicates the vulnerability of the enteric nervous system to exogenous influences, even in adults. As an example, it is possible that acquired diseases of the enteric nervous system, such as achalasia, may result from a loss of ENPC, analogous to congenital disorders, such as Hirschsprung’s. The ability to identify the adult ENPC will therefore enable a new understanding of the pathogenesis of enteric neuromuscular diseases as well as the development of novel regenerative therapies.

5 November 2021 in Science Advances
Verified
Journal Article
Open access
QXQian Xu
Qian Xu
NFNeil C. Ford
Neil C. Ford
SHShaoqiu He
Shaoqiu He
QHQian Huang
Qian Huang
MAMichael Anderson
Michael Anderson
XDXinzhong Dong
Xinzhong Dong
Spinal cord astrocytes represent an important component of pain gating and exert nonneuronal control of pain.

13 May 2017 in Neuroscience Bulletin
Verified
Journal Article
Open access
PDF file
MAMichael Anderson
Michael Anderson
QZQin Zheng
Qin Zheng
XDXinzhong Dong
Xinzhong Dong
Due to the complex circuitry and plethora of cell types involved in somatosensation, it is becoming increasingly important to be able to observe cellular activity at the population level. In addition, since cells rely on an intricate variety of extracellular factors, it is important to strive to maintain the physiological environment. Many electrophysiological techniques require the implementation of artificially-produced physiological environments and it can be difficult to assess the activity of many cells simultaneously. Moreover, imaging Ca2+ transients using Ca2+-sensitive dyes often requires in vitro preparations or in vivo injections, which can lead to variable expression levels. With the development of more sensitive genetically-encoded Ca2+ indicators (GECIs) it is now possible to observe changes in Ca2+ transients in large populations of cells at the same time. Recently, groups have used a GECI called GCaMP to address fundamental questions in somatosensation. Researchers can now induce GCaMP expression in the mouse genome using viral or gene knock-in approaches and observe the activity of populations of cells in the pain pathway such as dorsal root ganglia (DRG), spinal neurons, or glia. This approach can be used in vivo and thus maintains the organism’s biological integrity. The implementation of GCaMP imaging has led to many advances in our understanding of somatosensation. Here, we review the current findings in pain research using GCaMP imaging as well as discussing potential methodological considerations.

1 June 2018 in Anesthesiology
Verified
Journal Article
Open access
PDF file
VTVinod Tiwari
Vinod Tiwari
MAMichael Anderson
Michael Anderson
FYFei Yang
Fei Yang
VTVineeta Tiwari
Vineeta Tiwari
QZQin Zheng
Qin Zheng
YGYun Guan
Yun Guan
Background: Ongoing neuropathic pain is difficult to treat. The authors examined whether dermorphin [D-Arg2, Lys4] (1–4) amide, a peripherally acting µ-opioid receptor agonist, attenuates ongoing pain-associated manifestations after nerve injury in rats and mice.Methods: Using conditioned place preference assay, the authors tested whether animals show a preference to the environment associated with drug treatment. Wide-dynamic range and dorsal root ganglion neuronal activities were measured by electrophysiology recording and calcium imaging.Results: Nerve-injured animals stayed longer in dermorphin [D-Arg2, Lys4] (1–4) amide–paired chamber after conditioning than during preconditioning (rats: 402.4 ± 61.3vs.322.1 ± 45.0 s, 10 mg/kg, n = 9,P= 0.009; mice: 437.8 ± 59.4vs.351.3 ± 95.9 s, 2 mg/kg, n = 8,P= 0.047). Topical ganglionic application of dermorphin [D-Arg2, Lys4] (1–4) amide (5 μM, 1 μl, n = 5) reduced the numbers of small-diameter dorsal root ganglion neurons that showed spontaneous activity (1.1 ± 0.4vs.1.5 ± 0.3,P= 0.044) and that were activated by test stimulation (15.5 ± 5.5vs.28.2 ± 8.2,P= 0.009) after injury. In neuropathic rats, dermorphin [D-Arg2, Lys4] (1–4) amide (10 mg/kg, n = 8) decreased spontaneous firing rates in wide-dynamic range neurons to 53.2 ± 46.6% of predrug level, and methylnaltrexone (5 mg/kg, n = 9) blocked dermorphin [D-Arg2, Lys4] (1–4) amide–induced place preference and inhibition of wide-dynamic range neurons. Dermorphin [D-Arg2, Lys4] (1–4) amide increased paw withdrawal threshold (17.5 ± 2.2 g) from baseline (3.5 ± 0.7 g, 10 mg/kg, n = 8,P= 0.002) in nerve-injured rats, but the effect diminished after repeated administrations.Conclusions: Peripherally acting μ-opioids may attenuate ongoing pain-related behavior and its neurophysiologic correlates. Yet, repeated administrations cause antiallodynic tolerance.